Natural killer T (NKT) cells comprise a specialized subset of T lymphocytes that express cell surface markers characteristic of NK cells. The ability of these cells to produce cytokines, activate cells of both the innate and adaptive immune responses, and recognize antigen in the context of CD1d molecules strongly suggest that NKT cells play a pivotal role in anti-tumor immunity. However, anti-tumor effects mediated by these cells may be compromised because cancer patients have a reduction in both NKT cell number and function. Therefore, we hypothesize that adoptive transfer of effector NKT cells will be an effective therapeutic strategy to enhance cancer immunotherapy. Our lab has previously developed MHC-lg and CD1d-lg-based artificial Antigen Presenting Cells (aAPC), which can facilitate the induction and expansion of primary T and NKT cells. In this proposal, we will further modify this CD1d-lg based aAPC to stimulate and analyze different NKT cell subsets in vitro. In addition we will evaluate the in vivo anti-tumor activity of the different NKT cell subsets in a human melanoma/SCID model. Collectively, these studies provide a novel approach to study the in vitro expansion as well as the in vitro and in vivo function of NKT cell subsets for potential use in adoptive cancer immunotherapy is presented. The information gained in the proposed studies will serve to help understand and design NKT cell based approaches to enhance current immunotherapeutic treatment strategies for cancer. A major goal in cancer immunotherapy is to generate an effective anti-tumor immune response. This application represents a novel approach using artificial Antigen Presenting Cells, aAPC, to study activation and expansion of NKT cells to enhance the efficiency of cancer immunotherapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Scientist Development Award - Research & Training (K01)
Project #
5K01CA131487-05
Application #
8289621
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ojeifo, John O
Project Start
2008-07-16
Project End
2013-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
5
Fiscal Year
2012
Total Cost
$99,730
Indirect Cost
$7,387
Name
University of Maryland Baltimore
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
188435911
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Sohn, Silke; Tiper, Irina; Japp, Emily et al. (2014) Development of a qPCR method to rapidly assess the function of NKT cells. J Immunol Methods 407:82-9
East, James E; Kennedy, Andrew J; Webb, Tonya J (2014) Raising the roof: the preferential pharmacological stimulation of Th1 and th2 responses mediated by NKT cells. Med Res Rev 34:45-76
Subrahmanyam, Priyanka B; Carey, Gregory B; Webb, Tonya J (2014) Bcl-xL regulates CD1d-mediated antigen presentation to NKT cells by altering CD1d trafficking through the endocytic pathway. J Immunol 193:2096-105
Li, Junxin; Sun, Wenji; Subrahmanyam, Priyanka B et al. (2014) NKT Cell Responses to B Cell Lymphoma. Med Sci (Basel) 2:82-97
Webb, Tonya J; Bieler, Joan G; Schneck, Jonathan P et al. (2009) Ex vivo induction and expansion of natural killer T cells by CD1d1-Ig coated artificial antigen presenting cells. J Immunol Methods 346:38-44